CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 70 enrolled
Drug / intervention
UB-312 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04075318
NCT04075318Phase 1Completed
CompareCT.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease

United Neuroscience Ltd.·interventional·Posted Aug 30, 2019·Updated Mar 6, 2025

In Brief

A Phase 1 clinical trial evaluating UB-312 and Placebo for Parkinson's Disease and Parkinsonism. Completed, enrolled 70 participants across 1 site.

Detailed Summary

This is a 44-week, randomized, placebo-controlled, double-blind, single-center, phase 1 clinical trial consisting of a dose-escalation Part A study in healthy participants, followed by a Part B in participants with Parkinson's disease with a selected doses from Part A.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease, Parkinsonism
CountriesNetherlands
CollaboratorsCentre for Human Drug Research, Netherlands, Worldwide Clinical Trials, Vaxxinity, Inc.

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedAug 30, 2019
Enrollment StartAug 29, 2019
Primary CompletionMar 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.8 years ago

Interventions

UB-312biological

A synthetic peptide-based vaccine

Placebobiological

Matching placebo